Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.10.0.1
Commitments and Contingencies (Details Narrative)
 3 Months Ended 9 Months Ended
Sep. 12, 2018
USD ($)
Apr. 05, 2018
USD ($)
Apr. 05, 2018
EUR (€)
Mar. 22, 2018
USD ($)
Jun. 14, 2017
USD ($)
Sep. 14, 2015
USD ($)
Dec. 24, 2013
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
Research and development costs               $ 3,454 $ 205,674 $ 70,249 $ 363,476  
Amortizing the retainer payment               2,294   4,587    
Unamortized balance of the retainer payment               13,761   13,761    
Unamortized balance of the retainer payment classified as a current asset               9,174   9,174    
Unamortized balance of the retainer payment classified as a non-current asset               $ 4,587   4,587  
Annual license maintenance fee                   25,000    
Payments on non-refundable milestone                   $ 1,897,000    
Percentage of milestone               40.00%   40.00%    
Royalties description                   The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances.    
First Four Years [Member]                        
Minimum payments for royalties                   $ 50,000    
Five Years and Thereafter [Member]                        
Minimum payments for royalties                   100,000    
First Quarter of Two Thousand Nineteen [Member]                        
Non refundable license issue fee                   25,000    
Collaboration Agreement Bio PharmaWorks LLC [Member]                        
Consulting and advisory fee           $ 10,000            
Collaboration agreement value               $ 0 30,000 10,000 60,000  
NDA Consulting Corp [Member]                        
Consulting and advisory fee             $ 4,000 4,000 4,000 12,000 12,000  
NINDS [Member]                        
Accrued expenses               50,000   50,000    
Theradex Systems, Inc [Member]                        
Costs under work $ 954,000                      
Materials Cooperative Research and Development Agreement [Member]                        
Funds provide for use in acquiring technical, statistical and administrative support for research activities         $ 100,000              
Research and development costs               $ 0 $ 12,500 25,000 $ 62,500  
Materials Cooperative Research and Development Agreement [Member] | First Installment [Member] | July 9, 2017 [Member]                        
Paid two equal installments                   50,000    
Materials Cooperative Research and Development Agreement [Member] | Second Installment [Member] | June 14, 2018 [Member]                        
Paid two equal installments                   $ 50,000    
Material Transfer Agreement [Member] | Development Milestones [Member] | INSERM [Member] | Maximum [Member]                        
Milestone payments       $ 1,750,000                
Material Transfer Agreement [Member] | Commercial Milestones [Member] | INSERM [Member] | Maximum [Member]                        
Milestone payments       $ 6,500,000                
Consulting Agreement with Liberi Life Consultancy BV [Member]                        
Agreement term   2 years 2 years                  
Payment of a fixed, one-time retainer one time retainer   $ 18,348                    
Net payments of sales of products or licensing activities, percentage   2.50% 2.50%                  
Consulting Agreement with Liberi Life Consultancy BV [Member] | EURO [Member]                        
Payment of a fixed, one-time retainer one time retainer | €     € 15,000